Yulia Slavina

Taysha Gene Therapies, Inc. prepares for Q2 2026 earnings release and company update

Taysha Gene Therapies, Inc. prepares for Q2 2026 earnings release and company update
Taysha Gene Therapies earnings preview

Taysha Gene Therapies, Inc. will disclose its financial results for the second quarter of 2026 and provide a corporate update next week.

The company has invited stakeholders to access additional information via its official website. This upcoming announcement is anticipated to give investors and analysts a clearer picture of the firm’s financial health and strategic direction. Details are being clarified.

Earlier this year, Taysha Gene Therapies secured a commercial supply agreement with Catalent for TSHA-102 as reported in a recent company update. The company’s stock traded at $5.86 after news of the Catalent partnership, according to market data published this month. These developments come ahead of the upcoming financial disclosure.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.